J

Johnson & Johnson

Makes prescription drugs and medical devices

Senior Plastic Surgery Sales Representative - Aesthetics and Reconstruction

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
$56k - $89.7k+ Sales incentives/commissions + Long-term incentive program
Mid, Senior
Bachelor's
Fresno, CA, USA+3 moreMore locations: California, USA | Modesto, CA, USA | Bakersfield, CA, USA
In PersonField-based role supporting the Fresno territory.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 4 years of outside sales experience is required.
  • 4–6 years of total work experience is required.
  • Typically oversees $1.5 million to $3.5 million in annual sales year over year, demonstrating sustained performance in 3 out of 4 years.
  • Surgical sales experience is preferred.
  • Knowledge of clinical and surgical techniques and procedures, and medical terminology, is preferred.
  • At least 4 years of sales experience with a documented history of 2 or more years of sales success in a medical device sales environment is preferred.
  • Experience selling to surgeons in an operating room environment and/or calling on plastic surgeons is preferred.
  • Aesthetics sales experience and experience calling on plastic surgeons is preferred.
Responsibilities
  • Demonstrate proper surgical use of products to physicians.
  • Address customer product questions and objections in accordance with the sales training methodology.
  • Maintain and expand current accounts, build new accounts, develop customer relationships, and meet sales quotas.
  • Execute the selling cycle professionally, ethically, and persuasively to prompt customer action.
  • Operate within defined budgetary limits.
  • Communicate business-related issues or opportunities to the next management level.
  • Ensure personal and company compliance with applicable federal, state, local, and company regulations, policies, and procedures.
  • Perform other assigned duties as needed.
  • Use product differentiation and business development skills to provide a consultative sales approach, including preparing pre-call plans, assessing customer needs, handling objections, presenting visual aids, closing, and following up.
  • Build strong customer relationships and hold customers accountable to commitments through frequent customer interaction.
  • Manage account growth, understand customer circumstances and needs, motivate customers to become product advocates, build strategic working relationships, develop and service key opinion leaders, and allocate marketing programs.
  • Position the Mentor portfolio for both augmentation and reconstruction settings.
  • Meet productivity goals across the product portfolio.
  • Manage and execute calls across private practices, surgery centers, and hospitals; assess territory metrics to develop and implement territory business plans.
  • Implement and promote marketing programs in private practice settings.
  • Meet sales training requirements and administrative requirements and timelines set by senior leadership and the regional manager.
  • Complete consignment audits before deadlines and manage the territory within regional travel and budget parameters.
  • Apply market knowledge and technical fluency across Mentor and competitive product portfolios, understand breast anatomy, and support studies and materials with expertise.
  • Understand how tactics support overall strategy, execute the marketing plan across the product portfolio, and articulate strategy to customers, management, and team members.
Desired Qualifications
  • Identify decision-makers and influence decisions.
  • Manage and prioritize workload, multitask, and manage a diverse mix of issues, responsibilities, and challenges.
  • Communicate and present effectively.
  • Manage budgets and expenses and execute plans.
  • Demonstrate strong computer skills.
  • Function effectively in a high-performance team and adapt to a rapidly changing environment.
  • Demonstrate strong organizational and prioritization skills.
  • Communicate scientific and clinical product features and benefits.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.